Company intelligence / Profile preview

IDbyDNA

San Carlos, California, United Statesprweb.com ↗

Ownership: Private
Employees: ~14
Development stage: Commercial

Overview

The Explify platform enables comprehensive metagenomic profiling for infectious disease diagnosis and pathogen identification. It can identify over 50,000 microorganisms and more than 3,000 pathogens in clinical samples. The technology has been commercialized through partnerships with major labs and hospitals globally; it was also used for COVID‑19 surveillance. No drug or therapeutic clinical trials are reported—focus remains on diagnostic accuracy and speed.

Therapeutic areas: Infectious Diseases
Modalities: Device (NGS-based diagnostics)Software (bioinformatics platform)Diagnostic test (metagenomic sequencing)
Industry: Molecular Diagnostics

Partnerships

IlluminaSynergy Laboratories

Beyond the preview

Go deeper on IDbyDNA.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IDbyDNA.

Explore the full profile